The Latest Biotechnology / Pharmaceuticals Articles from Streetwise Reports


Derm Biopharma Named Top Growth Pick For 2022

Research Report
  ()
Journey Medical should increase 2022 and 2023 revenue by at least 30% such that it could turn a profit in 2024, noted a ROTH Capital Partners report.

Breaking News

This Pharmaceutical Company Has a Brilliant Concept

Contributed Opinion
  ()
Algernon Pharmaceuticals is a clinical-stage, small biotech that boasts a massive pipeline of lower risk and efficient drugs. Catalysts abound with this genius repurposing company.

Ph1 Trial Results of Dementia Drug Positive

Research Report
  ()
Anavex Life Sciences' study of Anavex 3-71 in frontotemporal dementia met primary and secondary safety endpoints, noted a Dawson James Securities report.

Biotech Co. Partners With Life Sciences Firms

Research Report
  ()
2seventy entered agreements with Novo Nordisk and Genevant to get an in vivo gene editing treatment for hemophilia A developed, noted a Wedbush report.

Enrollment Done for COVID-19 Drug Trial

Research Report
  ()
Part 2 of First Wave BioPharma's RESERVOIR trial of niclosamide to remove the SARS-CoV-2 virus from the GI tract is underway, noted a ROTH Capital Partners report.

2022 to Be Catalyst Rich for Biopharma

Research Report
  ()
The potential stock-moving events for Infinity Pharmaceuticals this year include the launch of two clinical trials and readouts from four studies, noted an H.C. Wainwright & Co. report.

Co.'s samRNA Vaccines Protect Better Against COVID Variants

Research Report
  ()
Gritstone bio Inc.'s lower-dose samRNA vaccines include a broader immune response to SARS-CoV-2 and may provide better protection against emerging variants. BTIG research has issued a "Buy" rating for Gritstone bio.

AI Driven Drug Firm Partners With Merck

  ()
Shares of Absci Corp. rose 18% after the company reported it is collaborating with Merck & Co. to create enzymes using its deep-learning Integrated Drug Creation™ platform and Bionic Protein™ technologies.

Co. Partners to Test New Cancer Vaccines

Research Report
  ()
Genocea Biosciences Inc. is teaming up with Janssen Biotech to explore the immunogenicity of neoantigens and the role and impact of Inhibigens™ in potential vaccine therapies for cancer. H.C. Wainwright & Co. advised that it currently has a "Buy" rating on Genocea.

Co. Plans to Make 100M Rapid COVID Tests Monthly

Research Report
  ()
Biopharmaceutical firm Sorrento Therapeutics Inc. plans to mobilize a fully automated assembly line in San Diego, Calif., capable of producing 6 million rapid antigen detection COVISTIX testing units per month starting in Q1/22.

New Muscular Dystrophy Drug Shows Promise

  ()
Edgewise Therapeutics shares traded 24% higher after the company reported its EDG-5506 significantly lowered muscle damage biomarkers in adults after just two weeks of dosing in its Becker muscular dystrophy trial.

Chen Lin's Top 6 Investment Ideas

  ()
In a recent interview with Streetwise Reports, family assets manager and contributing writer, Chen Lin, shared the six (mostly mid-cap) companies that are his top investment picks for 2022.

Lead Cancer Drug Gets Fast Tracked

  ()
Shares of Genprex Inc. traded 165% higher after the company reported the U.S. FDA has awarded Fast Track Designation for its REQORSA™ Immunogene Therapy for use in combination with Merck & Co.'s Keytruda® for non-small cell lung cancer treatment.

Analyst: Drug a 'Hidden Gem for 2022'

Research Report
  ()
Oppenheimer ranks Astria Therapeutics Outperform after learning about its drug for hereditary angioedema, saying "We stay bullish."

Co. Still Compelling After Drug Trial Failure

Research Report
  ()
"Arcalyst remains the value driver" for Kiniksa Pharmaceuticals, and "we continue to hold a favorable view of the company," noted a Wedbush report.

Co. Looks To US For Help Fighting Strokes

  ()
Canadian company Algernon Pharmaceuticals Inc. has applied to uplist to the Nasdaq in hopes of attracting U.S. investors to its mission to repurpose drugs.

Co. Rated Outperform As Heart Failure Drug Nears Potential Approval

Research Report
  ()
"Cytokinetics' pipeline of muscle-directed therapies has potential to address several diseases with high unmet medical need and may generate significant revenue across pipeline programs," noted an Oppenheimer report.

Analyst: Question Lingers Over Biotech’s Cell Therapy

Research Report
  ()
A DawsonJames report notes that Brainstorm Cell Therapeutics’ autologous stem cells in amyotrophic lateral sclerosis will need further study to prove their effectiveness.

Coverage Initiated on Biopharma Co. After Turnaround Story

Research Report
  ()
"With Acasti Pharma shares trading near cash levels yet current resources sufficient to achieve key development milestones across the pipeline over 2022-2023, we recommend investors build a position," noted an Oppenheimer report.

Analyst Highlights Top Picks in Biotech for 2022

Research Report
  ()
Aldeyra Therapeutics, in the ophthalmology space, and SQZ Biotechnologies, in the cell therapy sector, have "advantages that their specific approaches allow," noted a BTIG report.

FDA Grants Approval for CNS-Focused Biopharma Firm's Bipolar Disorder Drug

  ()
Intra-Cellular Therapies Inc. shares traded 19% higher to a new 52-week high after the company reported the U.S. FDA has approved the use of its CAPLYTA® (lumateperone) for treatment of adults with bipolar depression.

Co. Launches Pivotal Phase in Alzheimer's Agitation Drug's Trial

Research Report
  ()
BioXcel Therapeutics' lead drug candidate for agitation in Alzheimer's disease patients could serve a substantial market, noted an H.C. Wainwright & Co. report.

Analyst Says Regeneron Could Be 'Biotech Champion'

Research Report
  ()
Regeneron Pharmaceuticals Inc.'s stock was up 36% in 2021 while the NASDAQ Biotechnology Index remained flat, Oppenheimer analyst Hartaj Singh reported in a Dec. 16 research note.

Showing Results: 1 to 25 of 112 Next

Get Our Streetwise Reports Resources Report Newsletter Free and be the first to know!

A valid email address is required to subscribe

More Experts

"I used the mill commissioning delay to add some positions in MAG."
– Chen Lin, What Is Chen Buying? What Is Chen Selling?
"GCN is an attractive speculative play here."
– Clive Maund, CliveMaund.com